This article includes discussion of N-acetylglutamate synthase deficiency (NAGSD), N-acetylglutamate synthase deficiency, NAGS deficiency, and N-acetylglutamate synthase deficiency. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.
N-acetylglutamate synthase deficiency is an inherited urea cycle disorder that causes hyperammonemia and neurologic sequelae, and most importantly, intellectual disability and early death. N-acetylglutamate synthase (NAGS) plays a determinant role in regulating the urea cycle at the entry point and connects energy metabolism with nitrogen disposal. Primary genetic enzyme deficiency almost invariably results in hyperammonemic coma within the first weeks of life (≤ 28 days; neonatal/early onset), whereas presentation at a later stage of life (> 28 days; late onset) has very rarely been reported so far. Biochemical markers include elevated plasma glutamine and normal to reduced L-arginine and/or L-citrulline concentrations on amino acid analysis. Diagnosis is established by molecular genetic analysis or, rarely, by enzymatic testing. Treatment consists of long-term oral therapy with N-carbamylglutamate. It should be noted, however, that a successful therapeutic trial with N-carbamylglutamate is not diagnostic of primary N-acetylglutamate synthase deficiency because the drug may also lower elevated ammonia concentrations in some patients with organic acidurias or carbamylphosphate synthetase 1 deficiency, especially when added to the emergency treatment. N-carbamylglutamate is potentially of use in the treatment of other secondary conditions that interfere with N-acetylglutamate synthase activity. Secondary functional deficiencies occur whenever the synthesis of either of the substrates, acetyl-CoA or glutamate, is insufficient or when other substrates (eg, acyl-CoA) interfere or compete with acetyl-CoA for NAGS activity. This is the case if intermediates of amino and/or fatty acid metabolism or certain drugs (eg, valproate or pivalate-ester antibiotics) accumulate.
Currently, international networks for rare metabolic diseases (UCDC, E-IMD, JUCDC) aim to more completely describe the natural history, especially the initial and evolving clinical phenotype of patients with urea cycle disorders, such as N-acetylglutamate synthase deficiency. Furthermore, they want to determine if the natural disease course can be favorably modulated by diagnostic and therapeutic interventions. These networks collect systematic data to improve the clinical knowledge, develop guidelines, and provide patients and professionals with reliable data on disease manifestation, complications, as well as long-term outcomes of urea cycle disorders. These networks include the Urea Cycle Disorders Consortium (UCDC), established in 2003, the European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD), established in 2011, and the Japanese Urea Cycle Disorders Consortium (JUCDC), established in 2012 (Summar et al 2014).
Historical note and terminology
N-acetylglutamate synthase deficiency (NAGSD) was first described in 1981 in a male baby and had presumably occurred in 2 of his siblings who died in the neonatal period (Bachmann et al 1981). N-acetylglutamate synthase deficiency was considered and the patient successfully treated with benzoate, and later with carbamylglutamate and arginine. N-acetylglutamate synthase deficiency is caused by a deficiency of N-acetylglutamate synthase, which catalyzes the synthesis of N-acetylglutamate from acetyl-CoA and glutamate.Ah Mew and Caldovic 2011).
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.